Literature DB >> 11578596

Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease.

E Rockenstein1, L A Hansen, M Mallory, J Q Trojanowski, D Galasko, E Masliah.   

Abstract

The main objective of this study was to determine if levels of alpha-, beta- and/or gamma-synuclein mRNAs are differentially affected in brains of Lewy body disease (LBD) and Alzheimer's disease (AD) patients, compared to controls. In control cases, highest levels of expression were observed in the neocortex and the lowest in basal ganglia and substantia nigra. beta-Synuclein was the most abundant message (75-80%), followed by gamma-synuclein (10-15%) and alpha-synuclein (8-10%). Analysis of the superior temporal cortex, a region selectively affected in LBD and AD, showed that compared to controls, levels of alpha-synuclein were increased in cases of diffuse LBD (DLBD), levels of beta-synuclein were decreased in AD and DLBD, and levels of gamma-synuclein were increased in AD cases. This study suggests that a critical balance among products of the synuclein gene is important to maintain normal brain function and that alterations in this balance might be associated with neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11578596     DOI: 10.1016/s0006-8993(01)02772-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  49 in total

1.  Following activation of the amyloid cascade, apolipoprotein E4 drives the in vivo oligomerization of amyloid-β resulting in neurodegeneration.

Authors:  Haim Belinson; Zehavit Kariv-Inbal; Rakez Kayed; Eliezer Masliah; Daniel M Michaelson
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

2.  Toward deciphering the mechanistic role of variations in the Rep1 repeat site in the transcription regulation of SNCA gene.

Authors:  A Afek; L Tagliafierro; O C Glenn; D B Lukatsky; R Gordan; O Chiba-Falek
Journal:  Neurogenetics       Date:  2018-05-05       Impact factor: 2.660

3.  Complex Effects of the ZSCAN21 Transcription Factor on Transcriptional Regulation of α-Synuclein in Primary Neuronal Cultures and in Vivo.

Authors:  Georgia Dermentzaki; Nikolaos Paschalidis; Panagiotis K Politis; Leonidas Stefanis
Journal:  J Biol Chem       Date:  2016-02-23       Impact factor: 5.157

4.  Proteomic identification of specifically carbonylated brain proteins in APP(NLh)/APP(NLh) × PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice model of Alzheimer disease as a function of age.

Authors:  Rukhsana Sultana; Renã A S Robinson; Fabio Di Domenico; Hafiz Mohmmad Abdul; Daret K St Clair; William R Markesbery; Jian Cai; William M Pierce; D Allan Butterfield
Journal:  J Proteomics       Date:  2011-06-25       Impact factor: 4.044

5.  SILAC-based proteomic analysis to investigate the impact of amyloid precursor protein expression in neuronal-like B103 cells.

Authors:  Dale Chaput; Lisa Hornbeck Kirouac; Harris Bell-Temin; Stanley M Stevens; Jaya Padmanabhan
Journal:  Electrophoresis       Date:  2012-12       Impact factor: 3.535

6.  Multiplication of the alpha-synuclein gene is not a common disease mechanism in Lewy body disease.

Authors:  Paul J Lockhart; Jennifer Kachergus; Sarah Lincoln; Mary Hulihan; Gina Bisceglio; Natalie Thomas; Dennis Dickson; Matthew J Farrer
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 7.  Neurobiology of alpha-synuclein.

Authors:  Kostas Vekrellis; Hardy J Rideout; Leonidas Stefanis
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

8.  Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy.

Authors:  Leslie Crews; Brian Spencer; Paula Desplats; Christina Patrick; Amy Paulino; Edward Rockenstein; Lawrence Hansen; Anthony Adame; Douglas Galasko; Eliezer Masliah
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

9.  Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?

Authors:  Manfred Windisch; Birgit Hutter-Paier; Edith Schreiner; Robert Wronski
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

10.  Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein.

Authors:  Natalia Ninkina; Owen Peters; Steven Millership; Hatem Salem; Herman van der Putten; Vladimir L Buchman
Journal:  Hum Mol Genet       Date:  2009-02-26       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.